The general mood among these heavyweight investors is divided, with 62% leaning bullish and 18% bearish. Among these notable ...

Deep-pocketed investors have adopted a bullish approach towards Regeneron Pharmaceuticals (NASDAQ:REGN), and it's something market players shouldn't ignore. Our tracking of public options records ...

S&P 500 dips 0.26% as tech stocks weigh on US indices. Traders eye Nvidia earnings and PCE data for market direction. Read ...

The researchers found that people who worked irregular shift patterns were 44% more likely ... A consortium of companies, led by Regeneron Pharmaceuticals, has already vowed to read and analyse ...

But, a substantial surprise in either direction could shift Federal Reserve rate-cut ... fourth-quarter earnings next week, starting with Regeneron Pharmaceuticals early Tuesday, followed by ...

A gene therapy from Regeneron Pharmaceuticals Inc. improved hearing in nearly all deaf children in a clinical trial, results that could allow the company to seek regulatory approval for the one ...

In my opinion, this strategic shift is also aimed at reducing dependence on sales of the Eylea franchise and Dupixent. Currently, the flagship of Regeneron's oncology franchise is Libtayo ...

In addressing the fourth-quarter figures for Eylea three weeks earlier at the J.P. Morgan Healthcare Conference, Regeneron had hoped to shift the focus of its quarterly call to positive news ...

Biotech company Regeneron (NASDAQ:REGN) reported Q4 CY2024 results topping the market’s revenue expectations , with sales up 10.3% year on year to $3.79 billion. Its non-GAAP profit of $12.07 ...

Regeneron (REGN) came out with quarterly earnings of $12.07 per share, beating the Zacks Consensus Estimate of $11.62 per share. This compares to earnings of $11.86 per share a year ago.